Advertisement
Canada markets closed

  • S&P/TSX

    21,969.24
    +83.86 (+0.38%)
     

  • S&P 500

    5,099.96
    +51.54 (+1.02%)
     

  • DOW

    38,239.66
    +153.86 (+0.40%)
     

  • CAD/USD

    0.7316
    -0.0007 (-0.09%)
     

  • CRUDE OIL

    83.66
    +0.09 (+0.11%)
     

  • Bitcoin CAD

    86,121.44
    -1,843.46 (-2.10%)
     

  • CMC Crypto 200

    1,320.51
    -76.02 (-5.44%)
     

  • GOLD FUTURES

    2,349.60
    +7.10 (+0.30%)
     

  • RUSSELL 2000

    2,002.00
    +20.88 (+1.05%)
     

  • 10-Yr Bond

    4.6690
    -0.0370 (-0.79%)
     

  • NASDAQ

    15,927.90
    +316.14 (+2.03%)
     

  • VOLATILITY

    15.03
    -0.34 (-2.21%)
     

  • FTSE

    8,139.83
    +60.97 (+0.75%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • CAD/EUR

    0.6838
    +0.0017 (+0.25%)
     

Falling Earnings Estimates Signal Weakness Ahead for Antares Pharma (ATRS)

Zacks Equity Research
Updated

Similar to wise buying decisions, exiting certain underperformers at the right time helps maximize portfolio returns. Selling off losers can be difficult, but if both the share price and estimates are falling, it could be time to get rid of the security before more losses hit your portfolio.

One such stock that you may want to consider dropping is Antares Pharma Inc. ATRS, which has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter and the current year. A Zacks Rank #5 (Strong Sell) further confirms weakness in ATRS.

A key reason for this move has been the negative trend in earnings estimate revisions. For the full year, we have seen 2 estimates moving down in the past 30 days, compared to no upward revision. This trend has caused the consensus estimate to trend lower, going from a loss of 1 cent per share a month ago to its current level of a loss of 8 cents per share.

Also, for the current quarter, Antares Pharma has seen 2 downward estimate revisions versus no revision in the opposite direction, dragging the consensus estimate down to a loss of 4 cents a share from a loss of 2 cents per share over the past 30 days.   

The stock also has seen some pretty dismal trading lately, as the share price has dropped 30.1% in the past month.

So it may not be a good decision to keep this stock in your portfolio anymore, at least if you don’t have a long time horizon to wait.

If you are still interested in the Medical/Dental-Supplies industry, you may instead consider a better-ranked stock - The Cooper Companies Inc. COO. The stock currently holds a Zacks Rank #2 (Buy) and may be better selection at this time.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
COOPER COS (COO): Free Stock Analysis Report
 
ANTARES PHARMA (ATRS): Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research